8-K
filed May 25, 2023, 7:59 PM ET
ticker RLMD
CIK 0001553643
other material
confidence high
sentiment neutral
materiality 0.40
Relmada Therapeutics stockholders approve plan amendment and elect directors
RELMADA THERAPEUTICS, INC.
- Stockholders approved amendment to 2021 Equity Incentive Plan, increasing authorized shares by 2,500,000 to 7,900,000.
- Charles J. Casamento and Sergio Traversa elected as Class II directors with 10,159,479 and 17,003,403 votes respectively.
- Ratification of Marcum LLP as independent auditor for fiscal 2023 approved with 22,048,083 votes.
- Approximately 76.9% of eligible common stock voted at the annual meeting held on May 25, 2023.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
RELMADA THERAPEUTICS, INC. shareholders approved Ratification of Appointment of Independent Auditors at the 2023-05-25 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-05-25
Exact text from the filing
Proposal 2: Ratification of Appointment of Independent Auditors. Stockholders approved the ratification of the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
RELMADA THERAPEUTICS, INC. shareholders approved Election of Directors at the 2023-05-25 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-05-25
Exact text from the filing
Proposal 1: Election of Directors. Stockholders elected the following nominees as directors to hold office until the 2026 Annual Meeting (i.e. as a Class II Director) and until his successor is elected and qualified.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.4
RELMADA THERAPEUTICS, INC. shareholders approved Approval of an amendment to the 2021 Plan at the 2023-05-25 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2023-05-25
Exact text from the filing
Proposal 3: Approval of an amendment to the 2021 Plan. Stockholders approved the amendment to the Company’s 2021 Plan described in
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.